Physician profile
Patrick H Win
NPI 1346335783
$257,705.14
in general payments reported to CMS, 2019-2025
26 companies · $36K in 2025
The $36K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $42K · 2021: $12K · 2022: $17K · 2023: $29K · 2024: $64K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $111K · Travel and Lodging: $11K · Food and Beverage: $6,674 · Consulting Fee: $698 · Education: $47.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,760.00 |
| Travel and Lodging | $11,320.64 |
| Food and Beverage | $6,673.59 |
| Consulting Fee | $697.50 |
| Education | $47.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185,343.44 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $42,640.28 | 2019-2025 | Xolair |
| Glaxosmithkline, LLC. | $12,494.10 | 2019-2025 | Nucala |
| Genentech, INC. | $7,770.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $5,109.33 | 2020-2025 | Dupixent |
| Amgen INC. | $1,117.89 | 2021-2025 | Tezspire |
| Genzyme Corporation | $1,034.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $688.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $482.19 | 2020-2025 | Cuvitru, Hyqvia |
| Optinose US, INC. | $428.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.10 | 2023 | Spravato |
| Pfizer INC. | $68.96 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $49.76 | 2019-2023 | |
| Csl Behring | $44.47 | 2025 | Haegarda, Andembry |
| Abbvie INC. | $38.46 | 2023 | Botox |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $26.89 | 2023 | Orladeyo |
| Horizon Therapeutics Plc | $24.52 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.56 | 2023 | Dysport |
| Octapharma USA, INC. | $21.28 | 2023 | Cutaquig |
| Kedrion Biopharma, INC. | $20.71 | 2024 | Albuked, Rhogam Ultra-Filtered Plus, Kedrab |
| Lilly USA, LLC | $20.30 | 2025 | Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.09 | 2022 | |
| Impel Pharmaceuticals INC. | $14.56 | 2023 | Trudhesa |
| Lundbeck LLC | $13.75 | 2024 | Vyepti |
| Biocryst Pharmaceuticals, INC. | $13.70 | 2023 | Orladeyo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$140,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Win listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.